Asthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneity

Pharmacogenomics

Volumn 10, Issue 5, 2009, Pages 753-767

  York, Timothy P ^a   Vargas Irwin, Cristina ^a   Anderson, Wayne H ^b   van den Oord, Edwin J C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Leukotriene; Mixture models; Montelukast; Pharmacogenetics; Placebo

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CYSTEINYL LEUKOTRIENE RECEPTOR 1; CYSTEINYL LEUKOTRIENE RECEPTOR 2; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR; MONTELUKAST; NORFLURANE; PLACEBO; SALBUTAMOL; UNCLASSIFIED DRUG;

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN GENE; ARACHIDONATE 5 LIPOXYGENASE GENE; ARTICLE; ASTHMA; CLINICAL TRIAL; CYSTEINYL LEUKOTRIENE RECEPTOR 1 GENE; CYSTEINYL LEUKOTRIENE RECEPTOR 2 GENE; DRUG RESPONSE; FINITE MIXTURE MODEL; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC VARIABILITY; HEREDITY; HUMAN; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PHARMACOGENETICS; STATISTICAL MODEL;

ANTI-ASTHMATIC AGENTS; ASTHMA; CARRIER PROTEINS; CYTOCHROME P-450 CYP3A; DRUG THERAPY; GENETIC MARKERS; GENOTYPE; HUMANS; MEMBRANE PROTEINS; MODELS, GENETIC; PHARMACOGENETICS; RECEPTORS, LEUKOTRIENE; SAMPLE SIZE;

EID: 66949160382     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.19     Document Type: Article

References (46)

1. Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
2. Vesell ES: Twin studies in pharmacogenetics. Hum. Genet. Suppl. 1, 19-30 (1978).
3. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
4. Rosmond R: Association studies of genetic polymorphisms in central obesity: a critical review. Int. J. Obes. Relat. Metab. Disord. 27, 1141-1151 (2003).
5. Duerr RH: The genetics of inflammatory bowel disease. Gastroenterol. Clin. North Am. 31, 63-76 (2002).
6. Kennedy JL, Fatter LA, Andreasen NC, Mayeux R, St George-Hyslop P: The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 302, 822-826 (2003).
7. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T: Clinial and genetic heterogeneity of latent autoimmune diabetes in adults. Diabetes Care 26, 2223, author reply 2224 (2003).
8. Hoffjan S, Ober C: Present status on the genetic studies of asthma. Curr. Opin. Immunol. 14, 709-717 (2002).
9. van den Oord E, McClay J, York T, Murrelle L, Robles J: Genetics and diagnostic refinement. Behav. Genet. 37, 535-545 (2007).
10. Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104 (2005).
11. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 58, 538-546 (1997).
12. Everitt BS, Hand DJ: Finite Mixture Distributions. Chapman and Hall, London, UK (1981).
13. Duan T, Finch SJ, Ye KQ, Chase GA, Mendell NR: Using mixture models to characterize disease-related traits. BMC. Genet. 6(Suppl. 1), S99 (2005).
14. Colder CR, Campbell RT, Ruel L, Richardson JL, Flay BR: A finite mixture model of growth trajectories of adolescent alcohol use: predictors and consequences. J. Consult Clin. Psychol. 70, 976-985 (2002).
15. Tsai HJ, Weeks DE: Comparison of methods incorporating quantitative covariates into affected sib pair linkage analysis. Genet. Epidemiol. 30, 77-93 (2006).
16. Lin S, Biswas S: On modeling locus heterogeneity using mixture distributions. BMC Genet. 5, 29 (2004).
17. van den Oord EJ: The use of mixture models to perform quantitative tests for linkage disequilibrium, maternal effects, and parent-of-origin effects with incomplete subject-parent triads. Behav. Genet. 30, 335-343 (2000).
18. Pearlman DS, White MV, Lieberman AK et al.: Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann. Allergy Asthma Immunol. 88, 227-235 (2002).
19. Calhoun WJ, Nelson HS, Nathan RA et al.: Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β(2)-agonists alone. Am. J. Respir. Crit. Care Med. 164, 759-763 (2001).
20. Klotsman M, York TP, Pillai SG et al.: Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genomics 17, 189-196 (2007).
21. Pinnas, JL, Noonan MJ, SF Weinstein et al.: Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. J. Asthma 42, 865-871 (2005).
22. Pearlman DS, Peden D, Condemi JJ et al.: Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J. Asthma 41, 797-806 (2004).
23. Rooklin A, Elkayam D, Weiler J: The fluticasone propionate salmeterol HFA MDI is significantly more efficacious in treating asthma than placebo HFA MDI, fluticasone propionate CFC MDI or salmeterol CFC MDI. J. Allergy Clin. Immunol. 107, S100 (2001).
24. Lumry WR, Conway MM, LaForce CF et al.: Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids. Ann. Allergy Asthma Immunol. 96, 51-59 (2006).
25. Estes WK: Traps in the route to models of memory and decision. Psychon. Bull. Rev. 9, 3-25 (2002).
26. Hanson S, Killeen PR: Measurement and modeling of behavior under fixed-interval schedules of reinforcement. J. Exp. Psychol. Anim. Behav. Process. 129-139 (1981).
27. Sidman M: Tactics of Scientific Research: Evaluating Experimental Data in Psychology. Basic Books, NY, USA (1960).
28. Cleveland W: Robust locally weighted regression and smoothing scatterplots. J. Am. Stat. Assoc. 74, 829-836 (1979).
29. Glass GV, Willson VL, Gottman JM: Design and analysis of time-series experiments. Information Age Publishing, NC, USA (1975).
30. Shine LC: Multi-subject behavior functions logically based on shines actualized and pure single-subject behavior functions. Educ. Psychol. Meas. 42, 783-788 (1982).
31. Muthen LK, Mutben BO: Mplus: User's Guide. Muthen and Muthen, CA, USA (1998).
32. Neale MC, Boker SM, Xie G, Maes HM: Mx: Statistical Modeling, 6th Edition. Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA (1999).
33. Kass RE, Raftery AE: Bayes Factors. J. Am. Stat. Assoc. 90, 773-795 (1995).
34. Keribin C: Consistent estimation of the order of mixture models. Ind. J. Stat. 62, 49-66 (1997).
35. Akaike H: New look at statistical model identification. IEEE Transactions on Automatic Control 19, 716-723 (1974).
36. 2 test statistic for moment structure analysis. Psychometrika 66, 507-514 (2001).
37. Hsueh HM, Chen JJ, Kodell RL: Comparison of methods for estimating the number of true null hypotheses in multiplicity testing. J. Biopharm. Stat. 13, 675-689 (2003).
38. Heise CE, O'Dowd BF, Figueroa DJ et al.: Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275, 30531-30536 (2000).
39. Gee C, Morrison JL, Thomas DC, Gauderman WJ: Segregation and linkage analysis for longitudinal measurements of a quantitative trait. BMC. Genet. 4(Suppl. 1), S21 (2003).
40. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
41. Allison DB: Transmission-disequilibrium tests for quantitative traits. Am. J. Hum. Genet. 60, 676-690 (1997).
42. Rabinowitz D: A transmission disequilibrium test for quantitative trait loci. Hum. Hered. 47, 342-350 (1997).
43. Xiong MM, Krushkal J, Boerwinkle E: TDT statistics for mapping quantitative trait loci. Ann. Hum. Genet. 62, 431-452 (1998).
44. Lima JJ, Zhang S, Grant A et al.: Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 173, 379-385 (2006).
45. Drazen JM, Yandava CN, Dube L et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22, 168-170 (1999).
46. Falconer DS, Mackay TFC: Introduction to quantitative genetics. Addison Wesley Longman, Essex, UK (1996).